Classification
- Anatomical main groupCCardiovascular system
- Therapeutic subgroupC02
- Pharmacological subgroupC02A
- Chemical subgroupC02AA
- Chemical substanceC02AA02Reserpine
Where it is registered
Each register and historical list with its number of registrations and a few of them.
At a glance
- ATC code
- C02AA02
- ATC group
- Cardiovascular system
- Registers
- 4
- Historical lists
- 1
- Registrations
- 65
- With their own page
- 55
- Companies
- 36
All medicines with Reserpine
Human medicines from every register that match Reserpine by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
65 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Reserpine | United States | 0.1MG, 0.25MG, 0.5MG … | tablet | Not marketed | Solvay |
| Reserpine and HydroflumethiazideCombination | United States | 50MG; 0.125MG | tablet | Not marketed | Ivax Pharms |
| Reserpine and HydrochlorothiazideCombination | United States | 25MG; 0.125MG, 50MG; 0.125MG | tablet | Not marketed | Barr |
| Reserpine and Hydrochlorothiazide-50Combination | United States | 50MG; 0.125MG | tablet | Not marketed | West Ward |
| Reserpine, Hydralazine Hydrochloride and HydrochlorothiazideCombination | United States | 25MG; 15MG; 0.1MG | tablet | Not marketed | Solvay |
| Reserpine, Hydrochlorothiazide, and Hydralazine HydrochlorideCombination | United States | 25MG; 15MG; 0.1MG | tablet | Not marketed | Lederle |
| Chlorothiazide-ReserpineCombination | United States | 250MG; 0.125MG, 500MG; 0.125MG | tablet | Not marketed | Pharmobedient |
| Chlorothiazide W/ ReserpineCombination | United States | 250MG; 0.125MG, 500MG; 0.125MG | tablet | Not marketed | Watson Labs |
| Chlorothiazide and ReserpineCombination | United States | 250MG; 0.125MG, 500MG; 0.125MG | tablet | Not marketed | Hikma |
| Trichlormethiazide W/ ReserpineCombination | United States | 0.1MG; 4MG | tablet | Not marketed | Watson Labs |
| Hydrochlorothiazide W/ ReserpineCombination | United States | 25MG; 0.125MG, 25MG; 0.1MG, 50MG; 0.125MG … | tablet | Not marketed | Watson Labs |
| Hydroflumethiazide and ReserpineCombination | United States | 25MG; 0.125MG, 50MG; 0.125MG | tablet | Not marketed | Usl Pharma |
| Hydralazine Hydrochloride-Hydrochlorothiazide-ReserpineCombination | United States | 25MG; 15MG; 0.1MG | tablet | Not marketed | Mylan |
| Hydralazine, Hydrochlorothiazide W/ ReserpineCombination | United States | 25MG; 15MG; 0.1MG | tablet | Not marketed | Watson Labs |
| Hydralazine Hydrochloride, Hydrochlorothiazide and ReserpineCombination | United States | 25MG; 15MG; 0.1MG | tablet | Not marketed | Ivax Sub Teva Pharms |
| Hydrochlorothiazide W/ Reserpine and HydralazineCombination | United States | 25MG; 15MG; 0.1MG | tablet | Not marketed | Watson Labs |
| Hiserpia | United States | 0.1MG, 0.25MG | tablet | Not marketed | Bowman Pharms |
| Serpivite | United States | 0.25MG | tablet | Not marketed | Vitarine |
| Serpate | United States | 0.1MG, 0.25MG | tablet | Not marketed | Vale |
| Serpalan | United States | 0.1MG, 0.25MG | tablet | Not marketed | Lannett |
| Serpasil | United States | 0.2MG/4ML | elixir | Not marketed | Novartis |
| Serpasil | United States | 2.5MG/ML | injectable | Not marketed | Novartis |
| Serpasil | United States | 0.1MG, 0.25MG, 1MG | tablet | Not marketed | Novartis |
| Serpanray | United States | 0.1MG, 0.25MG, 1MG | tablet | Not marketed | Panray |
| Rau-Sed | United States | 0.1MG, 0.25MG, 0.5MG … | tablet | Not marketed | Bristol Myers Squibb |